

Frazier Healthcare Partners funds Takeda's biopharmaceutical venture

Client News

May 15, 2019

Gunderson Dettmer client Frazier Healthcare Partners has led the \$90 million financing of a biopharmaceutical firm focused on gastrointestinal issues created by Takeda Pharmaceutical. As part of the deal the new company, Phathom, will have control of development and exclusive commercial rights for an acid blocker known as vonoprazan.

In the [announcement of the new venture](#) Frazier Venture Partner Dr. Tachi Yamada said, "We are excited to have the opportunity to develop vonoprazan for the U.S., Europe and Canada to address this immense unmet need. Phathom represents a truly unique opportunity to launch a new company around a highly experienced, world-class team developing a late-stage product candidate supported by strong clinical data and commercial experience."

The Gunderson Dettmer deal team was led by Tim Ehrlich and Albert Vanderlaan and included Jay Hachigian and Samantha Gross.

Related People





Timothy H. Ehrlich
PARTNER
P +1 617 648 9399



Jay K. Hachigian
PARTNER
P +1 617 648 9101

Featured Insights

CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

INSIGHTS

Client Insight: California AI Transparency Act